Torisel is the investigational – untried new drug formulation developed by one of the world leaders in pharmaceutical sectors known as Wyeth Pharmaceuticals, indicated for the treatment of patients having advanced stage RCC. The new drug is said to have the most effect ingredient called Temsirolimus. The company is still continuing the Torisel studies in the phase 3 trial of patients having mantle cell lymphoma and is also preparing and performing various added studies in the Renal Cell Carcinoma - RCC as well as other solid tumor indications. 

Besides this, the added primary oncology trials with Torisel are under progress through specific co-operative research and development agreements with the National Cancer Institute for numerous other types of tumors. Torisel has been designed to reduce the mammalian target of rapamycin – mTOR kinase, the protein within all the cells that controls production of cell, growth of the cell as well as survival of cells. The new drug Torisel would be the first ever mTOR reducer for the treatment of cancer, if it get the formal approvals form the Food and Drugs Administration – FDA.

Wyeth would pursue making Torisel available to the patients who fulfills several criteria through the expanded access program – EAP, even during the prolonged review phase, in the United States. However, the U.S. FDA has earlier granted the fast track term besides orphan drug category for the new drug Temsirolimus used for the treatment of advanced stage Renal Cell Carcinoma – RCC.

Renal Cell Carcinoma – RCC is considered such a type of cancer that it is exceptionally difficult to treat and not only that, there is consistent demand of newer therapies for fighting or treating this ailment. Torisel has exhibited its power for helping to meets such significant medical demands.